Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-8,307
Closed -$207K 278
2025
Q4
$207K Sell
8,307
-435
-5% -$11K 0.06% 298
2025
Q3
$214K Sell
8,742
-2,200
-20% -$54.3K 0.06% 292
2025
Q2
$265K Sell
10,942
-687
-6% -$16K 0.07% 277
2025
Q1
$295K Sell
11,629
-4,178
-26% -$109K 0.08% 252
2024
Q4
$419K Buy
15,807
+655
+4% +$17.8K 0.12% 187
2024
Q3
$438K Sell
15,152
-170
-1% -$4.96K 0.13% 180
2024
Q2
$429K Buy
15,322
+2,133
+16% +$58.7K 0.14% 169
2024
Q1
$358K Buy
+13,189
New +$366K 0.13% 175
2023
Q3
Sell
-28,453
Closed -$1.04M 193
2023
Q2
$1.04M Buy
28,453
+6,885
+32% +$268K 0.45% 52
2023
Q1
$880K Buy
21,568
+4,254
+25% +$184K 0.67% 34
2022
Q4
$887K Buy
+17,314
New +$830K 0.74% 33

Other funds holding PFE

TFB Advisors's PFE Position: Q1 2026 in Review

TFB Advisors sold out of Pfizer (PFE) in Q1 2026, closing a stake of 8,307 shares — an estimated $207K sold.

TFB Advisors first reported a position in PFE in Q4 2022 and held it in 11 quarters. The position peaked at $1.04M in Q2 2023. 2,952 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • TFB Advisors reported no remaining Pfizer position as of Q1 2026 after selling out during the quarter.
  • TFB Advisors sold 8,307 Pfizer shares in Q1 2026, an estimated $207K.
  • TFB Advisors first reported a position in Pfizer in Q4 2022 and held it in 11 quarters.
  • TFB Advisors's Pfizer position peaked at $1.04M in Q2 2023.
  • 2,952 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on TFB Advisors's 13F filing for Q1 2026, filed 20 Apr 2026.